Impax Laboratories (IPXL) Receives News Sentiment Score of 0.32

Impax Labs

Impax Labs

(NASDAQ:IPXL) by 6.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,393 shares of the specialty pharmaceutical company's stock after selling 5,965 shares during the period.

Impax Laboratories Inc (NASDAQ:IPXL) institutional sentiment decreased to 1.18 in Q4 2016. Moreover, Sector Gamma As has 1.24% invested in the company for 499,153 shares. State of Alaska Department of Revenue increased its position in Impax Laboratories by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company's stock worth $102,000 after buying an additional 150 shares during the period. Columbus Circle Investors purchased a new stake in Impax Laboratories during the first quarter valued at $532,000. Legato Capital Management LLC raised its stake in Impax Laboratories by 1,165.0% in the first quarter. Louisiana State Employees Retirement System raised its stake in Impax Laboratories by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 30,000 shares of the specialty pharmaceutical company's stock valued at $380,000 after buying an additional 300 shares in the last quarter.

11/07/2016 - Impax Laboratories, Inc. was downgraded to "underperform" by analysts at Bank of America Merrill Lynch. Bank of Montreal Can now owns 53,874 shares of the specialty pharmaceutical company's stock worth $681,000 after buying an additional 20,288 shares during the period.

03/27/2017 - Impax Laboratories, Inc. had its "buy" rating reiterated by analysts at Guggenheim. (NASDAQ:IPXL) opened at 18.25 on Wednesday. The stock's market capitalization is $1.31 billion.

Traders are a little more bullish on shares of Impax Laboratories, Inc. of late if you put credence in the downtick in short interest.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.12 by $0.01. It is negative, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. The firm had revenue of $184.40 million during the quarter, compared to the consensus estimate of $193.17 million. Analysts expect next quarter's EPS will be $0.20 and the next full year EPS is anticipated to be $1.08. The business's revenue was down 18.2% on a year-over-year basis. Pnc Services Grp has invested 0% in Impax Laboratories Inc (NASDAQ:IPXL).

COPYRIGHT VIOLATION WARNING: This news story was posted by BBNS and is the property of of BBNS. If you are accessing this news story on another site, it was illegally copied and reposted in violation of worldwide trademark & copyright legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/impax-laboratories-inc-ipxl-shares-sold-by-nationwide-fund-advisors-updated-updated-updated/1078082.html.

A number of research firms have recently weighed in on IPXL. Royal Bank Of Canada set a $15.00 target price on shares of Impax Laboratories and gave the stock a "hold" rating in a report on Sunday. Deutsche Bank AG set a $21.00 price target on shares of Impax Laboratories and gave the company a "buy" rating in a research report on Monday. Zacks Investment Research cut Impax Laboratories from a "buy" rating to a "hold" rating in a research note on Monday. Piper Jaffray Companies raised shares of Impax Laboratories from an "underweight" rating to a "neutral" rating and raised their target price for the company from $9.00 to $16.00 in a research note on Tuesday. On November 14, 2016 the stock rating was rated "Hold" in a report from Wallachbeth which is down from the previous "Buy" rating. Company shares last traded at $18.38 which is marginally over $15.78, the stock's 50 day moving average and just above the 200 day moving average of $13.40.

Impax Laboratories, Inc is a specialty pharmaceutical company. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, in addition to the development and marketing of branded products. The Impax Specialty Pharma is involved in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.